The lawsuit was filed in connection with Sun Pharma‘s submission of abbreviated new drug application (ANDA) seeking marketing rights for the generic versions of Depomed‘s 500mg and 1000mg strengths of Glumetza before the expiration of the five US patents: 6,340,475, 6,488,962, 6,635,280, 6,723,340, and 7,780,987.
Depomed has filed the suit within 45 days required to stay, or bar, the FDA from approving Sun Pharma’s ANDA for 30 months or until a district court decision that is adverse to the patents, whichever may occur earlier.
Depomed senior vice president and general counsel Matthew Gosling said Depomed will continue to vigorously enforce its intellectual property rights with respect to their Glumetza products.